Mesoblast publishes results of AMI trial

Mesoblast (ASX:MSB) has reported strong results from an animal trial of its allogeneic adult stem cells in acute myocardial infarction (AMI).

The study results, published in the May 2013 issue of Circulation Research, show that intercoronary infusion of Mesoblast’s mesenchymal precursor cells (MPCs) was found to be safe and effective.

During the study, sheep were given an infusion of MPCs directly after an anterior AMI. A single infusion decreased infarct size by 40%, increased capillary density by 71% and increased arteriole density 127%.

The treatment also helped stave off left ventricular adverse remodelling and caused a market reduction of left ventricular volumes. The combined effect was an improvement in both global and regional cardiac function.

Mesoblast is using the results from the study as the basis for its phase IIa/IIb AMICI (Allogeneic Mesenchymal precursor cell Infusion in myoCardial Infarction) trials.

The company is now recruiting for the trials in Europe, Australia and New Zealand, and aims to conclude the study by mid-2016.

Mesoblast is also conducting clinical trials into using its MPCs in congestive heart failure in partnership with Teva Pharmaceuticals. The companies plan to commence a phase III trial this year.

Mesoblast is developing its MPC technology for a range of other indications, including diabetes, kidney diseases, and joint and spine conditions.

Mesoblast shares were trading 0.28% higher at $5.455 as of around 1.30 pm on Friday.